14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TLX vs APLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Telix Pharmaceuticals Limited (TLX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin).
Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs APLS. Trailing 12-month operating profitability (TLX 6.2% vs APLS 9.9%) and valuation multiples (TLX N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment41.4% of Rev ($369M)
90D Engineering Disclosures0 Published
APLS Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment54.4% of Rev ($601M)
90D Engineering Disclosures0 Published
Investor FAQ TLX vs APLS Key Questions & Quantitative Answers
As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Telix Pharmaceuticals Limited (TLX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
APLS leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with APLS at +60.9% YoY revenue growth and +0.0% YoY earnings growth on $1.11B TTM revenue (64.3% gross margin, 9.9% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus $1.11B for APLS. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($601M) (0 disclosures) for APLS.
APLS screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas APLS trades at 46.3x Forward P/E, 38.3x Trailing P/E, N/M PEG, and 4.8x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus APLS (46.0% ROE) capital efficiency.
In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, APLS carries 0.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.89x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.54β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.